Coenzyme Q10 Softens Methotrexate-Related Salivary Gland Injury in Rats
Methotrexate can protect against cancer and inflammatory disease while still injuring tissues that depend on constant redox balance. In this rat study, the salivary gland emerged as one of those vulnerable targets, with methotrexate driving oxidative stress, inflammatory activation, and visible tissue injury across both the parotid and submandibular glands. The countermeasure was coenzyme Q10, a mitochondrial cofactor with antioxidant and anti-inflammatory activity that blunted much of the damage when given alongside methotrexate.
The experiment used adult male albino rats divided into four groups: untreated control, CoQ10 alone, methotrexate alone, and methotrexate plus CoQ10. Methotrexate was delivered intraperitoneally at 20 mg/kg once weekly, while CoQ10 was administered orally at 100 mg/kg/day for 6 weeks. The design was straightforward, but the biology behind it was not. Salivary glands are metabolically active organs with continuous secretory demand, and repeated oxidative insult can quickly translate into xerostomia, impaired oral function, and downstream dental and mucosal complications.
One sentence captures the central result: methotrexate damaged the glands, and CoQ10 partially preserved them.
Oxidative Stress Drove the Biochemical Injury
Biochemical testing gave the injury a molecular signature. Methotrexate increased malondialdehyde and nitric oxide, both of which reflect oxidative membrane injury and nitrosative stress, while depressing reduced glutathione and the antioxidant enzymes superoxide dismutase, catalase, and glutathione peroxidase. TNF-α and IL-6 also rose, placing the salivary gland injury squarely in the overlap between oxidative stress and inflammatory signaling. In a glandular tissue that depends on intact membranes, healthy mitochondria, and coordinated secretion, this combination is especially destructive.
CoQ10 shifted that profile in the opposite direction. Co-administration restored antioxidant balance, lowered inflammatory cytokines, and reduced the biochemical footprint of tissue stress. Mechanistically, that makes sense: CoQ10 sits in the mitochondrial electron transport chain and helps stabilize energy production while limiting the oxidative spillover that follows mitochondrial dysfunction. When a toxicant such as methotrexate pushes cells toward ROS accumulation, a molecule that supports electron transport and scavenges free radicals can plausibly interrupt the cascade before structural failure becomes irreversible.
Histology Showed Less Acinar Collapse and Fibrosis
The tissue sections made the biochemical findings visible. In the methotrexate group, histology revealed severe acinar degeneration, inflammatory cell infiltration, and increased collagen deposition. Masson’s trichrome staining showed the fibrotic response clearly, suggesting that the injury had moved beyond transient metabolic stress into architectural remodeling. Salivary glands do not tolerate that kind of disruption quietly; once acinar units degenerate and interstitial collagen accumulates, secretory function can fall sharply.
CoQ10 reduced those abnormalities. Glandular architecture looked better preserved, and the histologic signs of inflammation and degeneration were less severe than in the methotrexate-only group. Histomorphometric assessment of acinar area also supported this pattern, showing recovery of structural integrity with CoQ10 supplementation. The difference mattered because acinar preservation is not a cosmetic endpoint. It is the anatomic substrate for saliva production, lubrication, buffering, antimicrobial defense, and oral comfort.
Ultrastructural Rescue Extended to the Cell Level
The electron microscopy findings pushed the story deeper into subcellular biology. Scanning and transmission electron microscopy confirmed marked surface and intracellular damage after methotrexate exposure. The study documented structural and ultrastructural abnormalities consistent with organelle injury and cellular dysfunction, which fits a toxic pattern driven by redox imbalance. Salivary gland cells rely on intact mitochondria and endoplasmic reticulum to maintain protein synthesis, secretion, and membrane trafficking; once those systems fail, the gland loses both form and function.
CoQ10 improved that ultrastructural picture. The treated glands showed more intact cellular organization and less disruption of the architecture seen in the methotrexate-only animals. In practical terms, the compound did more than lower biochemical markers. It preserved the cellular machinery that keeps salivary glands operational under stress.
What the Rat Model Suggests for Oral Toxicity During Methotrexate Therapy
Methotrexate-related salivary gland toxicity is clinically relevant because xerostomia affects swallowing, speech, taste, dental health, and mucosal integrity. Patients receiving methotrexate for malignant or inflammatory disease can develop oral symptoms that are easy to dismiss but difficult to ignore once established. This experiment suggests that oxidative stress is not a side effect in the abstract; it is a driving mechanism of glandular injury, fibrosis, and secretory compromise.
CoQ10 looks biologically plausible as a supportive adjunct because it targets the same pathways methotrexate perturbs: mitochondrial efficiency, lipid peroxidation, and inflammatory signaling. The findings support a preventive rather than rescue-oriented model, in which antioxidant support begins with methotrexate exposure and continues through the period of repeated injury. Still, the evidence remains preclinical. Rat salivary glands are not human salivary glands, and the dose used here cannot be assumed to translate directly into a safe or effective human regimen.
The study also leaves important clinical questions open. Human pharmacokinetics, long-term safety, and interaction with methotrexate efficacy were not addressed. Neither were symptom-based outcomes such as subjective dryness, salivary flow, oral mucosal health, or dental complications. Those endpoints will determine whether a biologically convincing laboratory signal becomes a usable supportive strategy in patients.
For now, the most concrete result is narrower: CoQ10 reduced methotrexate-induced salivary gland injury in rats by reversing oxidative stress, damping inflammation, and preserving gland structure at the histologic and ultrastructural levels. Whether that protection survives in human treatment remains an unanswered translational step, not a settled clinical recommendation.